Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stalevo in Early Parkinson's Disease
NCT04952194Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of levodopa in Parkinson's disease (PD), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Occurrence and frequency of dyskinesia at 1 year. Status: unknown.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04952194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952194.